Clinical and Economic Impact of Implementing OVIVA Criteria on Patients With Bone and Joint Infections in Outpatient Parenteral Antimicrobial Therapy.
Michael Marks 
;
Lucy CK Bell;
Imogen Jones;
Tommy Rampling;
Katharina Kranzer ;
Stephen Morris-Jones;
Sarah Logan;
Gabriele Pollara;
(2019)
Clinical and Economic Impact of Implementing OVIVA Criteria on Patients With Bone and Joint Infections in Outpatient Parenteral Antimicrobial Therapy.
Clinical infectious diseases, 71 (1).
pp. 207-210.
ISSN 1058-4838
DOI: 10.1093/cid/ciz991
;
Lucy CK Bell;
Imogen Jones;
Tommy Rampling;
Katharina Kranzer ;
Stephen Morris-Jones;
Sarah Logan;
Gabriele Pollara;
(2019)
Clinical and Economic Impact of Implementing OVIVA Criteria on Patients With Bone and Joint Infections in Outpatient Parenteral Antimicrobial Therapy.
Clinical infectious diseases, 71 (1).
pp. 207-210.
ISSN 1058-4838
DOI: 10.1093/cid/ciz991
The OVIVA study demonstrated noninferiority for managing bone and joint infections (BJIs) with oral antibiotics. We report that 79.7% of OPAT patients being treated for BJIs at our center would be eligible for oral antibiotics, saving a median (IQR) 19.5 IV-antibiotic days (8.5-37) and GBP 1234 (569-2594) per patient.
-
picture_as_pdf - Clinical and economic impact of implementing OVIVA criteria on patients with bone and joint infections in OPAT.pdf
-
subject - Accepted Version
-
- Available under Creative Commons: 3.0
Downloads